Boston Scientific is the Only Company Offering a Drug-Eluting Stent and Drug-Coated Balloon

Eluvia™ Drug-Eluting Stent and Ranger™ Drug-Coated Balloon are the only PAD devices backed by Level-1, Head-to-Head, Randomized Controlled Trials that demonstrate exceptional outcomes with differentiated technology – helping physicians make better, data-driven treatment decisions with a best-in-class drug-eluting portfolio.


Ranger image

Ranger™ Paclitaxel-Coated PTA Balloon Catheter

Supported by robust clinical evidence, Ranger provides exceptional outcomes, effortless deliverability, and efficient drug transfer.


Eluvia™ Drug-Eluting Vascular Stent System

Eluvia provides consistent, durable outcomes in challenging SFA disease and features a polymer design for controlled drug release.


Strengthen Quality Outcomes

Boston Scientific is the only company providing Level-1 Head-to-Head Randomized Controlled Clinical Trials in the PAD space for DES and DCB, helping physicians make more informed treatment decisions.


Enhance Patient Experience

Ranger DCB and Eluvia DES were purposely designed to deliver the lowest possible drug dose through efficient drug transfer to achieve high patency with low systemic drug exposure to the patient.


Increase Operational Efficiencies

Ranger DCB is .014” guidewire compatible to help streamline atherectomy procedures. Eluvia DES has shown to reduce hospital length of stay and readmission rates.


Improve Financial Health

Boston Scientific is the only company offering both DES and DCB, with the largest PI portfolio to streamline hospital supply chain management.


Eluvia and Ranger are registered or unregistered trademarks of Boston Scientific Corporation or its affiliates. All other trademarks are the property of their respective owners.


Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.